JW (Cayman) Therapeutics Co (HKSE:02126) Long-Term Capital Lease Obligation : HK$44.1 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Long-Term Capital Lease Obligation?

JW (Cayman) Therapeutics Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$44.1 Mil.

JW (Cayman) Therapeutics Co's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (HK$37.7 Mil) to Jun. 2023 (HK$43.1 Mil) and increased from Jun. 2023 (HK$43.1 Mil) to Dec. 2023 (HK$44.1 Mil).

JW (Cayman) Therapeutics Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (HK$39.0 Mil) to Dec. 2022 (HK$37.7 Mil) but then increased from Dec. 2022 (HK$37.7 Mil) to Dec. 2023 (HK$44.1 Mil).

JW (Cayman) Therapeutics Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Long-Term Capital Lease Obligation Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

18.77

15.07

39.00

37.67

44.07

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial						39.00	45.34	37.67	43.10	44.07

JW (Cayman) Therapeutics Co (HKSE:02126) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

JW (Cayman) Therapeutics Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines